In 1960, the Food and Drug Administration approved the first oral contraceptive pill for women. It reshaped careers, relationships, and the very fabric of modern society. Six decades later, male contraception still essentially consists of either condoms or a vasectomy. One is disposable, the other is surgery. Innovation, apparently, stalled in the 1920s with latex condoms.
The usual excuse is biology. Women release one egg per month whereas men produce millions of sperm every day. Turning off ovulation is a lot simpler than shutting down an ongoing production line. This is fair to some degree and cannot be disputed.
Yet, biology does not explain why risk tolerance shifts depending on who bears it. In 2016, a male hormonal-contraceptive trial funded by the World Health Organisation was halted after participants reported mood changes, acne, and altered libido. Sound familiar? These are the same side effects that millions of women face while on the pill.
This asymmetry is striking. Pregnancy carries medical danger, economic cost, and social consequences. Because women face these risks, pharmaceutical side effects are seen as more acceptable. When men do not face pregnancy, the same side effects appear less tolerable and therefore avoidable. Risk is easier to justify when it is not yours to bear.
Commercial incentives further compound this issue. Pharmaceutical companies operate on the principle of predictable markets. Female contraception products have a guaranteed consumer base with decades of established demand, whereas there is no guarantee that a similar counterpart would be met with any demand from male consumers. This perception and newer liability calculations leads to hesitation in the boardroom, slowing progress as effectively as any failed compound in the lab.
In 2022, scientists at the University of Minnesota announced a new, non-invasive discovery. They found promising preclinical results for YCT 529, a non-hormonal drug that inhibits sperm development without interfering with testosterone production. When tested on mice, the drug reduced pregnancy rates by nearly one hundred percent and fertility returned back to normal after treatment stopped. Human trials are now under way.
Another approach targets sperm mobility rather than the production itself. Researchers are investigating drugs that can temporarily paralyse sperm cells by interfering with proteins required for mobility. Instead of shutting down the factory, they sabotage the engine.
Then, there are long acting injectable treatments. RISUG, developed in India, and its US counterpart Vasalgel, are drugs which involve injecting a polymer into the sperm duct to block sperm transport. The method is designed to be reversible with a second injection that dissolves the polymer. Early trials have shown prolonged contraceptive effects. NEXT Life Sciences has announced Plan A, a treatment which uses the Vasalgel technology for male contraception. This product will be available to the public in 2026. Unlike a vasectomy, these treatments do not surgically remove tissue.
Male contraception is no longer an abstract possibility. It is entering clinical pipelines and becoming available to the public. The question is shifting from “can we build it” to “will it be adopted.” A reliable, reversible male pill would not simply expand choice. It would redistribute responsibility in a field historically shaped by asymmetry.
Science is finally catching up. Will society follow?
Photo by Reproductive Health Supplies Coalition on Unsplash